SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections [Yahoo! Finance]
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
SCYNEXIS, Inc. (NASDAQ: SCYX) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]